Literature DB >> 7770245

Chemotherapy-induced apoptosis in epithelial ovarian cancers.

L J Havrilesky1, A Elbendary, J A Hurteau, R S Whitaker, G C Rodriguez, A Berchuck.   

Abstract

OBJECTIVE: To determine whether chemotherapy drugs elicit programmed cell death (apoptosis) in ovarian cancer cells.
METHODS: Monolayers of immortalized ovarian cancer cell lines and primary ovarian cancer cells obtained from ascites were grown in the presence of cisplatin, 4-hydroxyperoxy-cyclophosphamide (the active metabolite of cyclophosphamide) or paclitaxel. Next, DNA was extracted from the cells and subjected to electrophoresis to determine if DNA laddering characteristic of apoptosis was present.
RESULTS: In three of six immortalized cell lines (OVCA 420, 429, and 433), apoptosis was not seen in response to any of the three drugs. In contrast, in OVCAR-3 and OVCA 432, DNA laddering consistent with apoptosis was observed in response to all three drugs. In the DOV 13 cell line, apoptosis was seen only with 4-hydroxyperoxycyclophosphamide. Among three primary ovarian cancers, cisplatin elicited apoptosis in one case. Both cell lines with mutant p53 genes (OVCAR-3 and OVCA 432) underwent apoptosis in response to all three drugs, whereas among three cell lines known to have normal p53 genes, one underwent apoptosis in response to 4-hydroxyperoxycyclophosphamide and two were unaffected.
CONCLUSION: Ovarian cancer cell death in response to commonly used chemotherapeutic drugs involves the induction of a genetically programmed sequence of events (apoptosis) rather than simply necrosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7770245     DOI: 10.1016/0029-7844(95)00058-y

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  13 in total

1.  High apoptosis-inducing and antitumor activities of the products of biological but not chemical cyclophosphamide activation.

Authors:  V I Kaledin; V P Nikolin; M R Galyamova; E D Vasil'eva; T Yu Baimak; N A Popova
Journal:  Dokl Biol Sci       Date:  2002 Sep-Oct

2.  Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.

Authors:  Michael G Woo; Kai Xue; Jiayin Liu; Heidi McBride; Benjamin K Tsang
Journal:  J Biol Chem       Date:  2011-11-23       Impact factor: 5.157

3.  Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses.

Authors:  Clarisse S Muenyi; Allan R Pinhas; Teresa W Fan; Guy N Brock; C William Helm; J Christopher States
Journal:  Toxicol Sci       Date:  2012-02-13       Impact factor: 4.849

4.  Rhizoctonia bataticola lectin induces apoptosis and inhibits metastasis in ovarian cancer cells by interacting with CA 125 antigen differentially expressed on ovarian cells.

Authors:  Prajna Hegde; Sindhura B R; Suhas Ballal; Bale M Swamy; Shashikala R Inamdar
Journal:  Glycoconj J       Date:  2021-11-08       Impact factor: 2.916

5.  A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.

Authors:  N Siddiqui; A V Boddy; H D Thomas; N P Bailey; L Robson; M J Lind; A H Calvert
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Paclitaxel-induced apoptosis in human ovarian cancer cell line COC1.

Authors:  S Wang; Y Lu; D Ma
Journal:  J Tongji Med Univ       Date:  1999

7.  Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.

Authors:  Peter W Schlosshauer; Wei Li; Kai-Ti Lin; Joseph L-K Chan; Lu-Hai Wang
Journal:  Gynecol Oncol       Date:  2009-07-02       Impact factor: 5.482

8.  Drug resistance in ovarian cancer - the role of p53.

Authors:  R Petty; A Evans; I Duncan; C Kurbacher; I Cree
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

9.  Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells.

Authors:  Yuanda Song; Palmer Wilkins; Wenhui Hu; Karnam S Murthy; Jing Chen; Zendra Lee; Regina Oyesanya; Jinhua Wu; Suzanne E Barbour; Xianjun Fang
Journal:  Biochem J       Date:  2007-09-15       Impact factor: 3.857

10.  Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.

Authors:  B Smith-Sørensen; J Kaern; R Holm; A Dørum; C Tropé; A L Børresen-Dale
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.